CPI-644 is a selective EP300/CBP bromodomain inhibitor, with an IC 50 of 0.18 µM against the CBP bromodomain. CPI-644 reduces the proportion of FOXP3 + cells and downregulates the expression of LAG-3 , CTLA-4 and PD-1 . CPI-644 can be used in cancer-related research.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Histone Acetyltransferase | Products > Signaling Pathways > LAG-3 | Products > Signaling Pathways > CTLA-4 | Products > Signaling Pathways > PD-1/PD-L1
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.